Cheng Andrew

CEO Cheng Andrew sold 30,000 shares of AKRO at $53.98; stock up 23.8% in 30 days, unprofitable company

Cheng Andrew, President and CEO, sold 30,000 shares (5.4% of pre-transaction holdings) at $53.98 on 2025-10-10, realizing $1,619,340.00 in proceeds. The sale occurred after a strong 23.8% 30-day rally and comes as the company reported negative net income of $-70,505,000.00 for its most recent full fiscal year. Within the same ticker, his four most recent sales (three on 2025-09-10 and one on 2025-09-11) have each generated 20.8%–25.3% post-sale gains within 30 days, though timing outcomes at the 90-day mark remain unmeasurable for all prior AKRO trades. His cross-ticker track record shows an average 90-day return of -0.2% following sells and a 61.54% well-timed rate, indicating mixed historical success at identifying inflection points before declines.

CEO Cheng Andrew sells 31,796 shares ($1.4M) across 4 transactions at $42.99–$44.62; stock down 24.5% from 52-week high.

Cheng Andrew, President and CEO of Akero Therapeutics, executed 4 separate sales totaling 31,796 shares (31.8K shares) for $1,374,665.15 ($1.4M) on September 10–11, 2025, at prices ranging from $42.99 to $44.62, reducing his holdings by 6.3% to 473,902 shares. The company remains unprofitable with a net loss of $70,505,000.00 over the most recent full fiscal year. Akero's stock has declined 24.5% from its 52-week high of $57.56 and is down 10.0% over the past 30 days, continuing a 21.9% decline over 90 days. The CEO's recent prior sales at this ticker on August 11 and July 10, 2025, have all shown negative returns: 30-day outcomes of -12.5%, -10.0%, -11.5%, -2.5%, and -0.2%, though 90-day outcomes on those earlier trades are not yet measurable.

CEO Cheng Andrew sold 30,000 shares (30.0K shares) for $1,457,595.98 in 3 separate transactions at AKRO on 2025-08-11; stock near 52-week lows.

Cheng Andrew, President and CEO, executed 3 separate sales totaling 30,000 shares (30.0K shares) for $1,457,595.98, reducing his holdings by 5.8% to 490,757 shares (490.8K shares). The sales occurred at prices between $48.07 and $49.44, while the stock currently trades at $48.31, down 16.1% from its 52-week high of $57.56 and down 8.4% over the past 30 days despite a 20.9% gain over the prior 90 days. The company is unprofitable with a net loss of $70,505,000.00 in its most recent full fiscal year. His same-ticker transaction history at AKRO shows 5 prior sells with mixed near-term results (30-day returns ranging from -0.2% to -4.3%), though longer-term timing outcomes remain unmeasurable. This large sale by the CEO during a period of stock weakness and amid operating losses warrants tracking to understand whether it reflects broader strategic reassessment or portfolio balancing by management.

CEO Andrew Cheng sells 30,000 AKRO shares for $1,534,894.87 across 2 transactions on 2025-07-10.

Andrew Cheng, President and CEO of Akero Therapeutics, executed 2 separate sales totaling 30,000 shares (30.0K shares) for $1,534,894.87 ($1.5M) at an average price of $51.16, reducing his holdings by 5.4% to 520,757 shares (520.8K shares). The current stock price of $51.57 is near the transaction prices and sits 10.4% below the 52-week high of $57.56, suggesting the sales occurred at a relative peak within the recent range. The company remains unprofitable with net income of $-70,725,000.00 ($-70.7M) over its most recent full fiscal year. Cheng's prior sales at AKRO have shown mixed near-term outcomes—three June sales declined 3.7% to 4.3% over 30 days, while two May sales rose 27.2% to 29.2% over 30 days—and his cross-ticker track record shows 20 prior sells with an average 90-day return of +4.6%, which indicates his sales have historically been poorly timed across his open-market trading history overall. The filing warrants review for context regarding the timing and volume of the sale relative to any company-specific developments.

AKRO CEO Cheng sold 37,837 shares at $54.05 avg for $2.0M; stock at 52-week highs near $57.56

Cheng Andrew, President and CEO, executed 3 separate sales totaling 37,837 shares for $2,044,939.67 at a blended average price of $54.05 on 2025-06-10, reducing his holdings by 6.4% to 556,487 shares. The sales occurred near the company's 52-week high of $57.56 (current price $53.56 is -7.0% from that peak), following a 33.9% surge over the prior 30 days and 21.3% gain over 90 days. Akero is unprofitable with net income of -$70,725,000 for the most recent full fiscal year. Across his cross-ticker track record of 20 prior sells, the insider's 90-day timing outcome has been mixed (70.59% well-timed rate), but at AKRO specifically, his 5 prior trades show 0 of 2 measurable 90-day sells were well-timed (both posted positive returns post-sale), suggesting his sales at this company have historically underperformed on timing.

CEO Andrew Cheng sold 30,000 shares ($1.2M) at $41.48 avg; stock at $40.01, down 30.5% from 52-week high

Cheng Andrew, President and CEO of Akero Therapeutics, executed 2 separate sales totaling 30,000 shares (30.0K shares) for $1,244,455.20 on 2025-05-12, reducing his holdings from 624,324 shares to 594,324 shares, a 4.8% decrease. The blended average sale price of $41.48 is modestly above the current market price of $40.01, placing the sales near recent trading levels. Akero reported a negative net income of $-70,725,000.00 for the most recent full fiscal year. His prior trades at this ticker show 2 of 2 measurable sales were well-timed at the 90-day mark (both followed by stock declines of -26.9% and -28.6%), and his cross-ticker track record across 20 prior sells demonstrates an 82.35% well-timed rate. The stock is currently down 19.1% over the past 90 days and down 30.5% from its 52-week high of $57.56.

CEO Cheng Andrew sold 30,000 shares of AKRO at $35.23; stock now -38.0% from 52-week high, down -22.2% in 30 days.

Cheng Andrew, President and CEO, sold 30,000 shares (representing -4.6% of pre-transaction holdings) on 2025-04-10 at $35.23, reducing his stake to 624.3K shares. The stock has declined -22.2% over the past 30 days and is -38.0% from its 52-week high of $57.56, trading now at $35.66. His prior trades at AKRO show a consistent pattern: five recent sales spanning February through March exhibited negative 30-day returns ranging from -10.5% to -15.9%, with no measurable 90-day outcomes yet to assess. The company is unprofitable with a -$72.7M net income over its most recent full fiscal year, operating in a $2.8B market cap. The convergence of significant price weakness post-sale, a series of recent insider sales, and underlying financial losses warrants observation of whether this represents continued liquidation amid deteriorating fundamentals.

CEO Cheng Andrew sold 30,000 shares for $1,253,069.47 at blended $41.77 (4.4% of holdings); stock up 57.9% in 90 days but down 10.4% in 30 days, company unprofitable.

CEO Andrew Cheng executed 2 separate sales totaling 30,000 shares for $1,253,069.47 on March 10, 2025, at a blended average price of $41.77, reducing his holdings from 686.1K to 656.1K shares. The sale occurred while the stock is -10.4% over the past 30 days despite a +57.9% surge over 90 days and a current price of $45.85, which is -20.3% below the 52-week high. His cross-ticker track record across 20 prior open-market sells shows a 75.00% well-timed rate with an average 90-day return of -10.6%, but his same-ticker history at AKRO shows 5 prior sells on February 10, 2025 with uniformly negative 30-day returns (-14.6% to -17.8%) and insufficient time-to-measurable-outcome data at the 90-day mark. The company reported a net loss of $-72.7M on a market cap of $3.7B, indicating ongoing unprofitability. The contrast between strong longer-term momentum and recent price weakness, combined with the company's negative earnings, presents investors with mixed signals about near-term momentum versus fundamental health.

AKRO CEO Cheng sells 30,000 shares across 5 transactions for $1.6M (2025-02-10) as stock rallies +101.1% in 30 days.

Akero Therapeutics CEO Andrew Cheng executed 5 separate sales totaling 30,000 shares for $1,581,994.19 on 2025-02-10, reducing his stake from 716.1K to 686.1K shares (-4.2%). The sales occurred at prices ranging from $51.75 to $55.81 (blended average $52.73), occurring within a period of significant recent momentum: the stock has surged +101.1% over the past 30 days and trades at 92% of its 52-week high of $57.56. Cheng's cross-ticker track record shows a 68.75% well-timed sell rate with a -7.5% average 90-day return, but at AKRO specifically, his prior measurable trade (2024-11-01) delivered a -13.3% 30-day return and +75.9% 90-day return—poorly timed against the eventual stock appreciation. The company remains unprofitable with net income of -$72,705,000.00 over its most recent full fiscal year, and the current trading price of $49.95 is now below the blended sale price of $52.73, indicating post-transaction depreciation.

CEO Cheng Andrew sold 30,000 AKRO shares for $1.6M at peak 52-week prices amid +93.1% rally in 30 days

Cheng Andrew (President and CEO) executed three separate sales totaling 30,000 shares for $1,646,977.98 on 2025-01-27, at a blended average price of $54.90. This sale occurred at the 52-week high of $54.00, following a dramatic 30-day rally of +93.1% and a 90-day rally of +75.2%. His cross-ticker track record shows 20 prior sells with an 82.35% well-timed rate (meaning 82.35% of those sales preceded subsequent stock declines over 90 days), though prior same-ticker outcomes at AKRO are mixed: 2 of 2 measurable 90-day outcomes showed declines (−25.2%, −23.8%), but two recent sales lack yet-measurable 90-day data. Post-sale, Cheng retains 716,062 shares (−4.0% of pre-transaction holdings). The company remains unprofitable with net income of $−72,705,000.00 for its most recent full fiscal year, raising the significance of executive liquidity actions at elevated valuations near year-highs.